EBOS ASX listing tomorrow
December 5, 2013
Symbion owner, New Zealand-listed
EBOS has confirmed that
the company’s application to
list on the ASX (PD 30 May) has
been approved and is slated for
tomorrow.
Code named EBO, trading will
commence on the ASX while the
primary listing of the company will
remain on the NZX.
EBOS managing director Mark
Waller says the dual listing on the
ASX will facilitate the ability of
Australian institutional and retail
investors to trade the Company’s
shares, deepening liquidity for the
benefit of all shareholders.
“The $1.1 billion acquisition
of Symbion earlier this year
transformed EBOS into the
largest diversified Australasian
marketer, wholesaler and
distributor of healthcare, medical
and pharmaceutical products by
revenue and a leading Australasian
animal care products marketer,
wholesaler and distributor.
“Since this acquisition we have
received increasing interest from
Australian investors who want to
participate in the EBOS growth
story,” Waller said.
EBOS gained further recognition
last week when it was awarded
“Best Growth Strategy” in the
Deloitte Top 200 Awards.
“EBOS is delighted to receive
recognition for its strategy which
continues to deliver exceptional
performance for our shareholders
amounting to compounding returns
of 19 per cent over the last 10
years,” says Waller.
The listing on the ASX is not
seeking any new capital, but rather
aims to provide access to and
visibility of the company’s shares
for Australian investors.
Shareholders will be able to trade
their stakes on either the ASX or
NZX, where this morning they are
worth NZ$9.15 each, valuing the
business at NZ$1.35 billion.
The Zuellig Group holds 40% of
the company.
A copy of the information
memorandum relating to the ASX
listing can be accessed HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Dec 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Dec 13
